Dilution? It is a push if you sell Series H to retire existing Series H. And it is an improvement when you sell Series H to retire existing Series E (which converts at 65% rather than 75% of the market price).

I thought that was the Monaco play all along. International Infusion raising funds through a sidepocket so they could take over and control the toxic financing to stop the converting and dumping.

Quote:

---

there's just no need to do it now. We were trying to get a sidepocket for the diagnostic or ESS. We need neither now. ESS is almost entirely paid for by CRADA and Diagnostic is a different ball game now with the triple merger. It's a good thing, whatever money we would have gotten from investors would have been at a mass dilutive cost. We need partner with cash or just to lay low, get out of the toxics, and let ESS prove itself.

---